– Reuters
Morgan Stanley Maintains Overweight on Western Midstream, Raises Price Target to $37
Morgan Stanley analyst Robert Kad maintains Western Midstream (NYSE:WES) with a Overweight and raises the price target from $35 to $37.
Related Posts
Wiliam Blair Issues Note Regarding New Guidelines On A ImmunoGen Drug, The National Comprehensive Cancer Network Just Released New Guideline Which Include Elahere, As A Preferred Regimen
The National Comprehensive Cancer Network (NCCN) just released new guidelines (Version
1.2023) for the treatment of ovarian cancer, which include Elahere (IMGN drug) as a preferred regimen. This comes as a particular surprise to the upside,
since it occurred faster than our (and likely the Street’s) expectations. It is our view that
$1000 Invested In Twitter 5 Years Ago Would Be Worth This Much Today
Twitter (NYSE:TWTR) has outperformed the market over the past 5 years by 5.19% on an annualized basis producing an average annual return of 14.97%. Currently, Twitter has a market capitalization of $30.66 billion.
Analyst Believes Value Of Core Square Seller, Branded Paypal Checkout, FIS Bank Software Assets ‘Undemanding’
KeyBanc analyst Josh Beck ran a SoTP analysis across extensive cap FinTech and walked away the most positive on Block,…